NEW YORK--(BUSINESS WIRE)---- $CAPR #CAPR--The law firm of Kirby McInerney LLP reminds investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:CAPR) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company. [LEARN MORE ABOUT THE CLASS ACTION] On May 5, 2025, Capricor issued a press releas
Related Questions
How does this lawsuit risk affect Capricor’s current valuation and price-to-earnings multiples?
What is the estimated financial exposure or potential settlement amount for Capricor?
How likely is it that the class action will lead to a material adverse effect (MAE) filing by the company?
Will the litigation trigger any covenant breaches, debt covenants, or risk of delisting for CAPR?
What is the likely timeline for resolution of the lawsuit (e.g., settlement, dismissal, trial)?
How might the reminder of the class action lawsuit affect CAPR's short-term price volatility?
What specific allegations are included in the securities fraud class action, and how do they compare to prior filings?
How does the risk profile from this lawsuit compare to similar biotech companies facing similar litigation?
What potential impact could this have on CAPR’s ability to raise capital or secure financing?
Are there any insider trading or insider selling patterns emerging following the notice?